Therefore, NF-κB inhibitors can inhibit obesity-induced hypertension by mitigating adiposity-mediated hyper-inflammation and releasing proinflammatory cytokines implicated in the pathogenesis of hypertension [62]. This evidence concerns the gene NFKB1 and obesity disorder.